Kyverna Therapeutics, Inc. (KYTX)Healthcare | Biotechnology | EmeryVille, United States | NasdaqGS
8.37 USD
-0.27
(-3.125%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 8.53 +0.16 (1.912%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:44 a.m. EDT
Kyverna Therapeutics presents a stark dichotomy between optimistic analyst targets and deteriorating market reality. While analysts project a mean price of $30.40, the stock has erased over half its value in the last year, trading near its 52-week low. This disconnect suggests the market is pricing in significant execution risks or clinical hurdles that analysts have yet to fully incorporate. Fundamentally, the company is burning cash with negative free cash flow and no dividend support, making it unsuitable for income investors. The recent 13% drop following a $100 million share offering highlights the pressure on management to raise capital, which often signals distress in biotech firms. Although the balance sheet currently shows a healthy current ratio, the relentless cash burn and lack of revenue growth make the long-term outlook precarious. For short-term traders, the heavy put positioning at the $10 level creates a potential resistance ceiling, while the low statistical forecast confidence indicates that price movements are currently driven by noise rather than a clear trend. Until there is concrete evidence of revenue generation or a successful commercial launch, the risk-reward profile remains skewed toward caution. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.061405 |
| MSTL | 0.061453 |
| AutoTheta | 0.061485 |
| AutoETS | 0.061486 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 0.49 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.043 |
| Excess Kurtosis | 0.43 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 19.932 |
| Market Cap | 517,629,632 |
| Forward P/E | -2.73 |
| Beta | 1.94 |
| Website | https://kyvernatx.com |
As of Aug. 22, 2026, 2:44 a.m. EDT: Speculators are positioning defensively with heavy put volume at the $10 strike for March 2027, suggesting a belief that the stock will struggle to recover from its lows. Conversely, call interest is concentrated at the $5 strike, indicating a floor expectation rather than a breakout thesis. Implied volatility remains elevated, reflecting uncertainty around the company's commercialization timeline and recent capital raising events.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.4066854 |
| Address1 | 5,980 Horton Street |
| Address2 | Suite 550 |
| All Time High | 30.6 |
| All Time Low | 1.78 |
| Ask | 8.5 |
| Ask Size | 1 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 718,040 |
| Average Daily Volume3 Month | 998,498 |
| Average Volume | 998,498 |
| Average Volume10Days | 718,040 |
| Beta | 1.937 |
| Bid | 8.43 |
| Bid Size | 1 |
| Book Value | 2.689 |
| City | EmeryVille |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.37 |
| Current Ratio | 9.058 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 8.54 |
| Day Low | 8.31 |
| Debt To Equity | 19.932 |
| Display Name | Kyverna Therapeutics |
| Earnings Timestamp End | 1,794,427,200 |
| Earnings Timestamp Start | 1,794,427,200 |
| Ebitda | -157,364,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.232 |
| Enterprise Value | 351,200,640 |
| Eps Current Year | -2.76956 |
| Eps Forward | -3.07119 |
| Eps Trailing Twelve Months | -2.83 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.1737 |
| Fifty Day Average Change | 0.19629955 |
| Fifty Day Average Change Percent | 0.024015997 |
| Fifty Two Week Change Percent | 140.66853 |
| Fifty Two Week High | 13.67 |
| Fifty Two Week High Change | -5.3 |
| Fifty Two Week High Change Percent | -0.38771033 |
| Fifty Two Week Low | 3.55 |
| Fifty Two Week Low Change | 4.8199997 |
| Fifty Two Week Low Change Percent | 1.3577464 |
| Fifty Two Week Range | 3.55 - 13.67 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,707,489,000,000 |
| Float Shares | 39,715,241 |
| Forward Eps | -3.07119 |
| Forward P E | -2.7253277 |
| Free Cashflow | -107,684,496 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 149 |
| Fullday Change | -0.27 |
| Fullday Change Percent | -3.12501 |
| Fullday Price | 8.53 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06979 |
| Held Percent Institutions | 0.78535 |
| Implied Shares Outstanding | 61,843,444 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-02-08 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California. |
| Long Name | Kyverna Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 517,629,632 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_650816865 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -152,638,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 534,018,138 |
| Number Of Analyst Opinions | 5 |
| Open | 8.52 |
| Operating Cashflow | -158,751,008 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 510 925 2492 |
| Post Market Change | 0.15999985 |
| Post Market Change Percent | 1.9115872 |
| Post Market Price | 8.53 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 8.64 |
| Price Eps Current Year | -3.0221405 |
| Price Hint | 2 |
| Price To Book | 3.1126814 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.746 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -0.27 |
| Regular Market Change Percent | -3.12501 |
| Regular Market Day High | 8.54 |
| Regular Market Day Low | 8.31 |
| Regular Market Day Range | 8.31 - 8.54 |
| Regular Market Open | 8.52 |
| Regular Market Previous Close | 8.64 |
| Regular Market Price | 8.37 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 524,689 |
| Return On Assets | -0.44511002 |
| Return On Equity | -0.8724 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 61,843,444 |
| Shares Percent Shares Out | 0.1374 |
| Shares Short | 8,498,858 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 7,846,393 |
| Short Name | Kyverna Therapeutics, Inc. |
| Short Percent Of Float | 0.16139999 |
| Short Ratio | 9.93 |
| Source Interval | 15 |
| State | CA |
| Symbol | KYTX |
| Target High Price | 33.0 |
| Target Low Price | 25.0 |
| Target Mean Price | 30.4 |
| Target Median Price | 32.0 |
| Total Cash | 199,427,008 |
| Total Cash Per Share | 3.225 |
| Total Debt | 32,998,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.83 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.3851 |
| Two Hundred Day Average Change | -0.015100479 |
| Two Hundred Day Average Change Percent | -0.0018008704 |
| Type Disp | Equity |
| Volume | 524,689 |
| Website | https://kyvernatx.com |
| Zip | 94,608 |